The purpose of this study is to help determine the best dose of inhaled albuterol sulfate in
premature babies at risk of developing bronchopulmonary dysplasia (BPD). BPD is the chronic
lung disease of prematurity and is associated with increased morbidity and mortality, longer
hospital stays, and increased healthcare utilization. Albuterol is an inhaled medication
frequently used in premature infants with chronic lung disease and in people with asthma. It
is believed to be safe, but the optimal dose for infants is not clear. The investigators
hypothesize that albuterol may help a subset of premature infants with lung disease, but they
need to determine the best dose prior to doing research about how effective it is for chronic
lung disease/BPD. Response to each of three doses of albuterol will be measure using
pulmonary function tests.